1-3 of 3
Tomer M. Mark
Close
Sort by
Journal Articles

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies

Olivia Perez de Acha, Lauren Reiman, David S. Jayabalan, Zachary J. Walker, Grace Bosma, Alana L. Keller, Sarah E. Parzych, Diana Abbott, Beau M. Idler, Drew Ribadeneyra, Ruben Niesvizky, Peter A. Forsberg, Tomer M. Mark, Daniel W. Sherbenou
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6430–6440.
https://doi.org/10.1182/bloodadvances.2023010162
Published: 2023
Includes: Supplemental data
Journal Articles

Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression

Clinical Trials & Observations
Zachary J. Walker, Michael J. VanWyngarden, Brett M. Stevens, Diana Abbott, Andrew Hammes, Christophe Langouët-Astrie, Clayton A. Smith, Brent E. Palmer, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, Daniel W. Sherbenou
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1628–1639.
https://doi.org/10.1182/bloodadvances.2019000122
Published: 2020
Includes: Supplemental data
Journal Articles

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma

Clinical Trials & Observations
Tomer M. Mark, Peter A. Forsberg, Adriana C. Rossi, Roger N. Pearse, Karen A. Pekle, Arthur Perry, Angelique Boyer, Linda Tegnestam, David Jayabalan, Morton Coleman, Ruben Niesvizky
Journal: Blood Advances
Blood Adv (2019) 3 (4): 603–611.
https://doi.org/10.1182/bloodadvances.2018028027
Published: 2019
Includes: Supplemental data